First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

NCT04767594 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

1407

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Palbociclib + endocrine therapy

Sponsor

Pfizer